Loading…

Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation

Congestive heart failure (CHF) is characterized by abnormal vasoconstriction and an impairment in nitric oxide (NO)-mediated vasodilatation. We have previously demonstrated that the decrease in sensitivity to NO lies at least partially at the level of the smooth muscle and is due to a reduction in t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of molecular and cellular cardiology 2006-09, Vol.41 (3), p.488-495
Main Authors: Chen, Frank C., Ogut, Ozgur, Rhee, Albert Y., Hoit, Brian D., Brozovich, Frank V.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3
cites cdi_FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3
container_end_page 495
container_issue 3
container_start_page 488
container_title Journal of molecular and cellular cardiology
container_volume 41
creator Chen, Frank C.
Ogut, Ozgur
Rhee, Albert Y.
Hoit, Brian D.
Brozovich, Frank V.
description Congestive heart failure (CHF) is characterized by abnormal vasoconstriction and an impairment in nitric oxide (NO)-mediated vasodilatation. We have previously demonstrated that the decrease in sensitivity to NO lies at least partially at the level of the smooth muscle and is due to a reduction in the relative expression of the leucine zipper positive (LZ +) isoform of the myosin targeting subunit (MYPT1) of myosin light chain phosphatase. We hypothesized that since the attenuated vasodilatory response to NO in CHF has been shown to be secondary to an increased activity of the renin–angiotensin system, angiotensin converting enzyme (ACE) inhibition could affect MYPT1 isoform expression. To test this hypothesis, a rat myocardial infarction (MI) model of CHF was used; following left coronary artery ligation, rats were divided into control and captopril-treated groups. A third group of rats was given prazosin for 4 weeks. In the untreated control group, left ventricular function (LVF) was reduced at 2 weeks post-MI and remained at this level. Captopril treatment attenuated the fall in LVF. In the control aorta and iliac artery, the expression of the LZ + MYPT1 isoform fell 44–52% between 2 and 4 weeks post-MI, whereas in animals treated with captopril, MYPT1 isoform expression did not change. A decrease in the sensitivity to cGMP-mediated smooth muscle relaxation occurred coincident with the decrease in LZ + MYPT1 expression. The change in LZ + MYPT1 expression was not due to the decrease in afterload, as prazosin therapy produced an improvement in LVF but did not increase the relative expression of LZ + MYPT1 isoform. These data suggest that ACE inhibition, unique from pure afterload reduction, prevents MYPT1 isoform switching, which would preserve normal flow, or NO-mediated vasodilatation.
doi_str_mv 10.1016/j.yjmcc.2006.05.018
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68856125</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022282806005839</els_id><sourcerecordid>68856125</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3</originalsourceid><addsrcrecordid>eNp9kE9v1DAQxS0EokvhEyAhn7gl-F-yzoEDWtFSqVU5wNny2pPGqyQOHu-i_fZ4uytx62lGmvdm5v0I-chZzRlvv-zq425yrhaMtTVrasb1K7LirGsq3Wj1mqwYE6ISWugr8g5xxxjrlJRvyRVvNW-UFCuCG7vkuKQw0iXBAeaMdDpGDDMdw9OQqRts6Zch4jLYbBFowNjHNFH8G7IbwvxEczyZEdIB6FxGdqTu9uFnNYEPNoOnB4vRh7H4c4jze_KmtyPCh0u9Jr9vvv_a_KjuH2_vNt_uK6eEzFV5EMTaSS3b1nMvhOXOCwWcudYqv_aN6KVXqmt7pzqunO0cg7UQbis0rLfymnw-711S_LMHzGYK6GAc7Qxxj6bVumm5aIpQnoUuRcQEvSlAJpuOhjNzYm125pm1ObE2rDGFdXF9uqzfb0vS_54L3CL4ehZACXkIkAy6ALMrVBK4bHwMLx74B3MHk-U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68856125</pqid></control><display><type>article</type><title>Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation</title><source>ScienceDirect Journals</source><creator>Chen, Frank C. ; Ogut, Ozgur ; Rhee, Albert Y. ; Hoit, Brian D. ; Brozovich, Frank V.</creator><creatorcontrib>Chen, Frank C. ; Ogut, Ozgur ; Rhee, Albert Y. ; Hoit, Brian D. ; Brozovich, Frank V.</creatorcontrib><description>Congestive heart failure (CHF) is characterized by abnormal vasoconstriction and an impairment in nitric oxide (NO)-mediated vasodilatation. We have previously demonstrated that the decrease in sensitivity to NO lies at least partially at the level of the smooth muscle and is due to a reduction in the relative expression of the leucine zipper positive (LZ +) isoform of the myosin targeting subunit (MYPT1) of myosin light chain phosphatase. We hypothesized that since the attenuated vasodilatory response to NO in CHF has been shown to be secondary to an increased activity of the renin–angiotensin system, angiotensin converting enzyme (ACE) inhibition could affect MYPT1 isoform expression. To test this hypothesis, a rat myocardial infarction (MI) model of CHF was used; following left coronary artery ligation, rats were divided into control and captopril-treated groups. A third group of rats was given prazosin for 4 weeks. In the untreated control group, left ventricular function (LVF) was reduced at 2 weeks post-MI and remained at this level. Captopril treatment attenuated the fall in LVF. In the control aorta and iliac artery, the expression of the LZ + MYPT1 isoform fell 44–52% between 2 and 4 weeks post-MI, whereas in animals treated with captopril, MYPT1 isoform expression did not change. A decrease in the sensitivity to cGMP-mediated smooth muscle relaxation occurred coincident with the decrease in LZ + MYPT1 expression. The change in LZ + MYPT1 expression was not due to the decrease in afterload, as prazosin therapy produced an improvement in LVF but did not increase the relative expression of LZ + MYPT1 isoform. These data suggest that ACE inhibition, unique from pure afterload reduction, prevents MYPT1 isoform switching, which would preserve normal flow, or NO-mediated vasodilatation.</description><identifier>ISSN: 0022-2828</identifier><identifier>EISSN: 1095-8584</identifier><identifier>DOI: 10.1016/j.yjmcc.2006.05.018</identifier><identifier>PMID: 16815432</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>ACE inhibition ; Animals ; Antihypertensive Agents - pharmacology ; Captopril - pharmacology ; Congestive heart failure ; Cyclic GMP - metabolism ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Echocardiography - methods ; Flow mediated vasodilatation ; Heart Failure ; Male ; Myosin phosphatase ; Myosin-Light-Chain Phosphatase - chemistry ; Myosin-Light-Chain Phosphatase - metabolism ; Myosins - chemistry ; Nitric oxide ; Nitric Oxide - chemistry ; Protein Isoforms ; Rats ; Rats, Sprague-Dawley ; Vascular reactivity ; Vasodilatation ; Vasodilator Agents - pharmacology</subject><ispartof>Journal of molecular and cellular cardiology, 2006-09, Vol.41 (3), p.488-495</ispartof><rights>2006 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3</citedby><cites>FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16815432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Frank C.</creatorcontrib><creatorcontrib>Ogut, Ozgur</creatorcontrib><creatorcontrib>Rhee, Albert Y.</creatorcontrib><creatorcontrib>Hoit, Brian D.</creatorcontrib><creatorcontrib>Brozovich, Frank V.</creatorcontrib><title>Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation</title><title>Journal of molecular and cellular cardiology</title><addtitle>J Mol Cell Cardiol</addtitle><description>Congestive heart failure (CHF) is characterized by abnormal vasoconstriction and an impairment in nitric oxide (NO)-mediated vasodilatation. We have previously demonstrated that the decrease in sensitivity to NO lies at least partially at the level of the smooth muscle and is due to a reduction in the relative expression of the leucine zipper positive (LZ +) isoform of the myosin targeting subunit (MYPT1) of myosin light chain phosphatase. We hypothesized that since the attenuated vasodilatory response to NO in CHF has been shown to be secondary to an increased activity of the renin–angiotensin system, angiotensin converting enzyme (ACE) inhibition could affect MYPT1 isoform expression. To test this hypothesis, a rat myocardial infarction (MI) model of CHF was used; following left coronary artery ligation, rats were divided into control and captopril-treated groups. A third group of rats was given prazosin for 4 weeks. In the untreated control group, left ventricular function (LVF) was reduced at 2 weeks post-MI and remained at this level. Captopril treatment attenuated the fall in LVF. In the control aorta and iliac artery, the expression of the LZ + MYPT1 isoform fell 44–52% between 2 and 4 weeks post-MI, whereas in animals treated with captopril, MYPT1 isoform expression did not change. A decrease in the sensitivity to cGMP-mediated smooth muscle relaxation occurred coincident with the decrease in LZ + MYPT1 expression. The change in LZ + MYPT1 expression was not due to the decrease in afterload, as prazosin therapy produced an improvement in LVF but did not increase the relative expression of LZ + MYPT1 isoform. These data suggest that ACE inhibition, unique from pure afterload reduction, prevents MYPT1 isoform switching, which would preserve normal flow, or NO-mediated vasodilatation.</description><subject>ACE inhibition</subject><subject>Animals</subject><subject>Antihypertensive Agents - pharmacology</subject><subject>Captopril - pharmacology</subject><subject>Congestive heart failure</subject><subject>Cyclic GMP - metabolism</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Echocardiography - methods</subject><subject>Flow mediated vasodilatation</subject><subject>Heart Failure</subject><subject>Male</subject><subject>Myosin phosphatase</subject><subject>Myosin-Light-Chain Phosphatase - chemistry</subject><subject>Myosin-Light-Chain Phosphatase - metabolism</subject><subject>Myosins - chemistry</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - chemistry</subject><subject>Protein Isoforms</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Vascular reactivity</subject><subject>Vasodilatation</subject><subject>Vasodilator Agents - pharmacology</subject><issn>0022-2828</issn><issn>1095-8584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNp9kE9v1DAQxS0EokvhEyAhn7gl-F-yzoEDWtFSqVU5wNny2pPGqyQOHu-i_fZ4uytx62lGmvdm5v0I-chZzRlvv-zq425yrhaMtTVrasb1K7LirGsq3Wj1mqwYE6ISWugr8g5xxxjrlJRvyRVvNW-UFCuCG7vkuKQw0iXBAeaMdDpGDDMdw9OQqRts6Zch4jLYbBFowNjHNFH8G7IbwvxEczyZEdIB6FxGdqTu9uFnNYEPNoOnB4vRh7H4c4jze_KmtyPCh0u9Jr9vvv_a_KjuH2_vNt_uK6eEzFV5EMTaSS3b1nMvhOXOCwWcudYqv_aN6KVXqmt7pzqunO0cg7UQbis0rLfymnw-711S_LMHzGYK6GAc7Qxxj6bVumm5aIpQnoUuRcQEvSlAJpuOhjNzYm125pm1ObE2rDGFdXF9uqzfb0vS_54L3CL4ehZACXkIkAy6ALMrVBK4bHwMLx74B3MHk-U</recordid><startdate>20060901</startdate><enddate>20060901</enddate><creator>Chen, Frank C.</creator><creator>Ogut, Ozgur</creator><creator>Rhee, Albert Y.</creator><creator>Hoit, Brian D.</creator><creator>Brozovich, Frank V.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060901</creationdate><title>Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation</title><author>Chen, Frank C. ; Ogut, Ozgur ; Rhee, Albert Y. ; Hoit, Brian D. ; Brozovich, Frank V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>ACE inhibition</topic><topic>Animals</topic><topic>Antihypertensive Agents - pharmacology</topic><topic>Captopril - pharmacology</topic><topic>Congestive heart failure</topic><topic>Cyclic GMP - metabolism</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Echocardiography - methods</topic><topic>Flow mediated vasodilatation</topic><topic>Heart Failure</topic><topic>Male</topic><topic>Myosin phosphatase</topic><topic>Myosin-Light-Chain Phosphatase - chemistry</topic><topic>Myosin-Light-Chain Phosphatase - metabolism</topic><topic>Myosins - chemistry</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - chemistry</topic><topic>Protein Isoforms</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Vascular reactivity</topic><topic>Vasodilatation</topic><topic>Vasodilator Agents - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Frank C.</creatorcontrib><creatorcontrib>Ogut, Ozgur</creatorcontrib><creatorcontrib>Rhee, Albert Y.</creatorcontrib><creatorcontrib>Hoit, Brian D.</creatorcontrib><creatorcontrib>Brozovich, Frank V.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of molecular and cellular cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Frank C.</au><au>Ogut, Ozgur</au><au>Rhee, Albert Y.</au><au>Hoit, Brian D.</au><au>Brozovich, Frank V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation</atitle><jtitle>Journal of molecular and cellular cardiology</jtitle><addtitle>J Mol Cell Cardiol</addtitle><date>2006-09-01</date><risdate>2006</risdate><volume>41</volume><issue>3</issue><spage>488</spage><epage>495</epage><pages>488-495</pages><issn>0022-2828</issn><eissn>1095-8584</eissn><abstract>Congestive heart failure (CHF) is characterized by abnormal vasoconstriction and an impairment in nitric oxide (NO)-mediated vasodilatation. We have previously demonstrated that the decrease in sensitivity to NO lies at least partially at the level of the smooth muscle and is due to a reduction in the relative expression of the leucine zipper positive (LZ +) isoform of the myosin targeting subunit (MYPT1) of myosin light chain phosphatase. We hypothesized that since the attenuated vasodilatory response to NO in CHF has been shown to be secondary to an increased activity of the renin–angiotensin system, angiotensin converting enzyme (ACE) inhibition could affect MYPT1 isoform expression. To test this hypothesis, a rat myocardial infarction (MI) model of CHF was used; following left coronary artery ligation, rats were divided into control and captopril-treated groups. A third group of rats was given prazosin for 4 weeks. In the untreated control group, left ventricular function (LVF) was reduced at 2 weeks post-MI and remained at this level. Captopril treatment attenuated the fall in LVF. In the control aorta and iliac artery, the expression of the LZ + MYPT1 isoform fell 44–52% between 2 and 4 weeks post-MI, whereas in animals treated with captopril, MYPT1 isoform expression did not change. A decrease in the sensitivity to cGMP-mediated smooth muscle relaxation occurred coincident with the decrease in LZ + MYPT1 expression. The change in LZ + MYPT1 expression was not due to the decrease in afterload, as prazosin therapy produced an improvement in LVF but did not increase the relative expression of LZ + MYPT1 isoform. These data suggest that ACE inhibition, unique from pure afterload reduction, prevents MYPT1 isoform switching, which would preserve normal flow, or NO-mediated vasodilatation.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>16815432</pmid><doi>10.1016/j.yjmcc.2006.05.018</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2828
ispartof Journal of molecular and cellular cardiology, 2006-09, Vol.41 (3), p.488-495
issn 0022-2828
1095-8584
language eng
recordid cdi_proquest_miscellaneous_68856125
source ScienceDirect Journals
subjects ACE inhibition
Animals
Antihypertensive Agents - pharmacology
Captopril - pharmacology
Congestive heart failure
Cyclic GMP - metabolism
Disease Models, Animal
Dose-Response Relationship, Drug
Echocardiography - methods
Flow mediated vasodilatation
Heart Failure
Male
Myosin phosphatase
Myosin-Light-Chain Phosphatase - chemistry
Myosin-Light-Chain Phosphatase - metabolism
Myosins - chemistry
Nitric oxide
Nitric Oxide - chemistry
Protein Isoforms
Rats
Rats, Sprague-Dawley
Vascular reactivity
Vasodilatation
Vasodilator Agents - pharmacology
title Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T01%3A38%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Captopril%20prevents%20myosin%20light%20chain%20phosphatase%20isoform%20switching%20to%20preserve%20normal%20cGMP-mediated%20vasodilatation&rft.jtitle=Journal%20of%20molecular%20and%20cellular%20cardiology&rft.au=Chen,%20Frank%20C.&rft.date=2006-09-01&rft.volume=41&rft.issue=3&rft.spage=488&rft.epage=495&rft.pages=488-495&rft.issn=0022-2828&rft.eissn=1095-8584&rft_id=info:doi/10.1016/j.yjmcc.2006.05.018&rft_dat=%3Cproquest_cross%3E68856125%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c423t-543e27c38366d1d22a1cd24e10c6a4d7d52f3d4496fc4914ca9c0e722cb28e7b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68856125&rft_id=info:pmid/16815432&rfr_iscdi=true